Although DC-based therapy post-HSCT boosted the CD4+ and CD8+ tumor-specific T cell proliferation, no difference in T cell response was observed between patients receiving DC therapy prior to auto-HSCT and those only receiving DC therapy post-HSCT [136]. Here, CD8A is linked to neoplasm.